Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas W Grosenbach

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|June 27, 2019
Preliminary Screening and In Vitro Confirmation of Orthopoxvirus AntiviralsDouglas W Grosenbach, Dennis E Hruby
Future Virology|August 13, 2011
Development of the small-molecule antiviral ST-246 as a smallpox therapeuticDouglas W Grosenbach, Robert Jordan, Dennis E Hruby
Cancer Detection and Prevention|November 15, 2002
Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunityJames W Hodge, Douglas W Grosenbach, Jeffrey Schlom
Current Opinion in Virology|June 19, 2013
Antiviral options for biodefenseChelsea M Byrd, Douglas W Grosenbach, Dennis E Hruby
Journal of Immunology (Baltimore, Md. : 1950)|September 9, 2005
Vaccines with enhanced costimulation maintain high avidity memory CTLSixun Yang, James W Hodge, Douglas W Grosenbach, et al.
Expert Review of Clinical Pharmacology|August 18, 2023
Emerging pharmacological strategies for treating and preventing mpoxDouglas W Grosenbach, Andrew T Russo, Emily D Blum, et al.
Cellular Immunology|June 12, 2003
A recombinant vector expressing transgenes for four T-cell costimulatory molecules (OX40L, B7-1, ICAM-1, LFA-3) induces sustained CD4+ and CD8+ T-cell activation, protection from apoptosis, and enhanced cytokine productionDouglas W Grosenbach, Jeffrey Schlom, Linda Gritz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2003
Vaccine therapy of established tumors in the absence of autoimmunityJames W Hodge, Douglas W Grosenbach, Wilhelmina M Aarts, et al.
Blood|July 10, 2007
IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunityMary T Litzinger, Romaine Fernando, Tyler J Curiel, et al.
Expert Review of Anti-Infective Therapy|February 2, 2023
Overview of the regulatory approval of tecovirimat intravenous formulation for treatment of smallpox: potential impact on smallpox outbreak response capabilities, and future tecovirimat development potentialAndrew T Russo, Douglas W Grosenbach, Kady M Honeychurch, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Methods in Molecular Biology (Clifton, N.J.)|June 27, 2019
Preliminary Screening and In Vitro Confirmation of Orthopoxvirus AntiviralsDouglas W Grosenbach, Dennis E Hruby
Future Virology|August 13, 2011
Development of the small-molecule antiviral ST-246 as a smallpox therapeuticDouglas W Grosenbach, Robert Jordan, Dennis E Hruby
Cancer Detection and Prevention|November 15, 2002
Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunityJames W Hodge, Douglas W Grosenbach, Jeffrey Schlom
Current Opinion in Virology|June 19, 2013
Antiviral options for biodefenseChelsea M Byrd, Douglas W Grosenbach, Dennis E Hruby
Journal of Immunology (Baltimore, Md. : 1950)|September 9, 2005
Vaccines with enhanced costimulation maintain high avidity memory CTLSixun Yang, James W Hodge, Douglas W Grosenbach, et al.
Expert Review of Clinical Pharmacology|August 18, 2023
Emerging pharmacological strategies for treating and preventing mpoxDouglas W Grosenbach, Andrew T Russo, Emily D Blum, et al.
Cellular Immunology|June 12, 2003
A recombinant vector expressing transgenes for four T-cell costimulatory molecules (OX40L, B7-1, ICAM-1, LFA-3) induces sustained CD4+ and CD8+ T-cell activation, protection from apoptosis, and enhanced cytokine productionDouglas W Grosenbach, Jeffrey Schlom, Linda Gritz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2003
Vaccine therapy of established tumors in the absence of autoimmunityJames W Hodge, Douglas W Grosenbach, Wilhelmina M Aarts, et al.
Blood|July 10, 2007
IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunityMary T Litzinger, Romaine Fernando, Tyler J Curiel, et al.
Expert Review of Anti-Infective Therapy|February 2, 2023
Overview of the regulatory approval of tecovirimat intravenous formulation for treatment of smallpox: potential impact on smallpox outbreak response capabilities, and future tecovirimat development potentialAndrew T Russo, Douglas W Grosenbach, Kady M Honeychurch, et al.
Pageof 4